Skip to main content
. 2011 Nov 23;54(24):8328–8342. doi: 10.1021/jm2007326

Table 1. Inhibition of CHK1 and CHK2 by Bicyclic and Tricyclic Compounds.

graphic file with name jm-2011-007326_0014.jpg

  CHK1 Inhibition IC50 (μM)a CHK2 Inhibition IC50 (μM)a Selectivity (CHK2/CHK1)b LE (kcal mol–1 non-H atom–1)c
2 1.0 (0.86, 1.2) 50 (26, 74) 50 0.38
4 1.5 (1.3, 1.8) n.d.d   0.27
5 3.2 (2.2, 4.2) 28 (13, 43) 9 0.31
6 0.43 (0.26, 0.60) 3.4 (±1.16)e 8 0.36
rac-7 3.2 (2.4, 3.9) 12 (11, 13) 4 0.37
(R)-7 3.0 (2.9, 3.2) 13 (11, 16) 4 0.37
(S)-7 2.3 (1.55, 3.0) 3.5 (2.3, 4.6) 2 0.38
8 0.88 (±0.21) e 19 (16, 23) 22 0.40
9 3.7 (3.2, 4.2) 10 (9.3, 11) 3 0.33
10 1.7 (1.7, 1.8) 23 (22, 24) 14 0.47
11 1.7 (1.7, 1.8) 11 (8.1, 14) 6 0.45
12 0.67 (0.53, 0.80) 16 (10, 21) 24 0.43
13 0.29 (±0.02)e 12 (6.8, 16) 41 0.43
a

IC50 determined in a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA).(33) Mean of two independent determinations; individual values in parentheses. Standard inhibitor staurosporine gave CHK1 IC50 = 2.1 (±1.8) nM and CHK2 IC50 = 27 (±8) nM.

b

Ratio of IC50 values (CHK2/CHK1).

c

Ligand efficiency (LE) calculated using LE = [−1.4 log10(IC50 (M))]/(number of heavy atoms).(37)

d

Not determined.

e

Mean (±SD) of at least three independent determinations.

HHS Vulnerability Disclosure